LUC00078I2 - Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta - Google Patents

Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta Download PDF

Info

Publication number
LUC00078I2
LUC00078I2 LU00078C LUC00078C LUC00078I2 LU C00078 I2 LUC00078 I2 LU C00078I2 LU 00078 C LU00078 C LU 00078C LU C00078 C LUC00078 C LU C00078C LU C00078 I2 LUC00078 I2 LU C00078I2
Authority
LU
Luxembourg
Prior art keywords
treatment
mediterranean fever
familial mediterranean
beta antibodies
beta
Prior art date
Application number
LU00078C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LUC00078I2 publication Critical patent/LUC00078I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
LU00078C 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta LUC00078I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (fr) 2005-10-26 2006-10-24 Nouvelle utilisation d' anticorps anti il-1beta
EP10181100A EP2332577A1 (fr) 2005-10-26 2006-10-24 Nouvelle utilisation de composés IL-1 béta

Publications (1)

Publication Number Publication Date
LUC00078I2 true LUC00078I2 (fr) 2018-08-14

Family

ID=37806690

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92326C LU92326I2 (fr) 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU00078C LUC00078I2 (fr) 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92326C LU92326I2 (fr) 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)

Country Status (28)

Country Link
US (8) US8105587B2 (fr)
EP (5) EP1940465B1 (fr)
JP (4) JP2009513645A (fr)
KR (3) KR101518064B1 (fr)
CN (2) CN102861332A (fr)
AU (1) AU2006306280B2 (fr)
BR (1) BRPI0617830B8 (fr)
CA (3) CA2963828A1 (fr)
CY (4) CY1113378T1 (fr)
DK (2) DK2848258T3 (fr)
ES (3) ES2662420T3 (fr)
HU (2) HUE036973T2 (fr)
IL (4) IL190545A (fr)
JO (2) JO2826B1 (fr)
LT (3) LT2848258T (fr)
LU (2) LU92326I2 (fr)
MA (1) MA29919B1 (fr)
NO (2) NO345888B1 (fr)
NZ (1) NZ567222A (fr)
PH (2) PH12013501287A1 (fr)
PL (2) PL1940465T3 (fr)
PT (2) PT1940465E (fr)
RU (2) RU2468817C2 (fr)
SI (2) SI1940465T1 (fr)
TN (1) TNSN08189A1 (fr)
TR (1) TR201802449T4 (fr)
TW (3) TWI537003B (fr)
WO (1) WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
EP2468301A1 (fr) * 2007-05-29 2012-06-27 Novartis AG Nouvelles indications pour une thérapie anti-IL-1-bêta
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
IN2012DN02634A (fr) * 2009-10-15 2015-09-04 Abbvie Inc
KR101539684B1 (ko) * 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
CN103517921B (zh) * 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
US11377656B2 (en) 2016-03-10 2022-07-05 Novartis Ag Chemically modified messenger RNA's
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
TW201946652A (zh) 2018-05-09 2019-12-16 瑞士商諾華公司 康納單抗(canakinumab)之用途
CN113227138A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β结合抗体的用途
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
EP3897613A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1bêta
BR112021011351A2 (pt) 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2023132698A1 (fr) * 2022-01-10 2023-07-13 (주)지아이이노베이션 Composition pharmaceutique pour la prévention ou le traitement des maladies cérébrales dégénératives, contenant un peptide-1 de type glucagon et un antagoniste du récepteur de l'interleukine-1

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690934A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
AU1513495A (en) 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL144492A0 (en) 1999-02-10 2002-05-23 Interleukin Genetics Inc Therapeutics and diagnostics based on an il-1b mutation
ES2228555T3 (es) * 1999-07-16 2005-04-16 Leo Pharma A/S Aminobenzofenonas con inhibidores de la il-1beta y tnf-alfa.
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AU2002221810B2 (en) 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
EP1423432A4 (fr) 2001-07-26 2006-01-11 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1beta)
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
WO2003049256A2 (fr) 2001-12-01 2003-06-12 Iskra Wind Turbine Manufacturers Limited Generateur de courant alternatif synchrone dote d'un mecanisme de freinage
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EP1496835A4 (fr) 2002-02-01 2006-10-18 Omeros Corp Compositions et methodes d'inhibition systemique de la degradation du cartilage
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US7083809B2 (en) * 2002-02-11 2006-08-01 Arkion Life Sciences, Llc Purified cytokine inhibitory factor
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
JP2006514021A (ja) 2002-12-09 2006-04-27 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法
EP1590369B1 (fr) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Antagonistes de l'il-1 beta humaine
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2545733A1 (fr) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
CA2567080A1 (fr) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Traitement de maladies a l'aide d'inhibiteurs de l'ice
EP1750746A1 (fr) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation d'antagonistes de l'il-1 dans le traitement de maladies auto-inflammatoires
WO2006079068A2 (fr) 2005-01-20 2006-07-27 University Of Rochester Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
EP1866428A2 (fr) 2005-03-18 2007-12-19 Microbia, Inc. Production de caroténoïdes dans de la levure ou des champignons oléagineux
DK1899378T3 (da) 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
TR201802449T4 (tr) 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.

Also Published As

Publication number Publication date
EP1940465B1 (fr) 2012-08-01
BRPI0617830A2 (pt) 2011-08-09
BRPI0617830B8 (pt) 2021-05-25
KR101749388B1 (ko) 2017-06-20
DK2848258T3 (en) 2018-03-19
CA2626214C (fr) 2016-06-21
AU2006306280A1 (en) 2007-05-03
EP2848258B1 (fr) 2017-12-13
SI2848258T1 (en) 2018-03-30
LTPA2018506I1 (lt) 2018-06-25
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
JP2009513645A (ja) 2009-04-02
EP2848258A1 (fr) 2015-03-18
ES2389110T3 (es) 2012-10-23
HUE036973T2 (hu) 2018-08-28
CA2898369C (fr) 2017-06-20
CA2898369A1 (fr) 2007-05-03
KR20080059598A (ko) 2008-06-30
PH12020500559A1 (en) 2021-06-14
NO345888B1 (no) 2021-09-27
PL1940465T3 (pl) 2013-01-31
RU2012133522A (ru) 2014-02-20
CY2018018I1 (el) 2018-12-12
JO2826B1 (en) 2014-09-15
TR201802449T4 (tr) 2018-03-21
CY1113378T1 (el) 2015-11-04
DK1940465T3 (da) 2012-10-22
AU2006306280B2 (en) 2010-06-17
IL277406A (en) 2020-11-30
CY2018018I2 (el) 2018-12-12
US20080286266A1 (en) 2008-11-20
US20240083997A1 (en) 2024-03-14
HK1252316A1 (en) 2019-05-24
TWI388335B (zh) 2013-03-11
EP3332807B1 (fr) 2023-02-22
CY2013046I1 (el) 2015-11-04
CN101291693B (zh) 2012-10-03
TW201617097A (zh) 2016-05-16
LTC2848258I2 (lt) 2019-08-12
IL245387A0 (en) 2016-06-30
EP4218815A3 (fr) 2024-03-27
EP1940465A2 (fr) 2008-07-09
PL2848258T3 (pl) 2018-06-29
JP2017206552A (ja) 2017-11-24
KR20150013834A (ko) 2015-02-05
CA2626214A1 (fr) 2007-05-03
MA29919B1 (fr) 2008-11-03
US20120039910A1 (en) 2012-02-16
JP6286403B2 (ja) 2018-02-28
RU2571563C2 (ru) 2015-12-20
PH12013501287B1 (en) 2016-02-01
EP3332807A2 (fr) 2018-06-13
LT2848258T (lt) 2018-02-26
US20150322148A1 (en) 2015-11-12
US20210147533A1 (en) 2021-05-20
HK1204767A1 (en) 2015-12-04
ES2662420T3 (es) 2018-04-06
EP3332807A3 (fr) 2018-06-20
CN102861332A (zh) 2013-01-09
WO2007050607A3 (fr) 2007-06-28
TW201302220A (zh) 2013-01-16
HUS1800025I1 (hu) 2018-07-30
RU2008120625A (ru) 2010-01-20
LU92326I2 (fr) 2014-02-05
SI1940465T1 (sl) 2012-10-30
JOP20140120B1 (ar) 2021-08-17
US8105587B2 (en) 2012-01-31
CA2963828A1 (fr) 2007-05-03
IL245387B (en) 2019-09-26
LTC1940465I2 (lt) 2017-12-11
EP4218815A2 (fr) 2023-08-02
CN101291693A (zh) 2008-10-22
KR20170038131A (ko) 2017-04-05
KR101518064B1 (ko) 2015-05-06
NO20082344L (no) 2008-07-22
US8409576B2 (en) 2013-04-02
IL190545A (en) 2016-09-29
HK1121041A1 (en) 2009-04-17
PT2848258T (pt) 2018-03-20
NO20200810A1 (no) 2008-07-22
ES2944067T3 (es) 2023-06-19
NZ567222A (en) 2011-07-29
EP2332577A1 (fr) 2011-06-15
IL258983B (en) 2020-10-29
US20170218063A1 (en) 2017-08-03
CY2013046I2 (el) 2015-11-04
TW200803898A (en) 2008-01-16
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
PH12013501287A1 (en) 2016-02-01
WO2007050607A2 (fr) 2007-05-03
LU92326I9 (fr) 2019-01-16
US20180201674A1 (en) 2018-07-19
IL190545A0 (en) 2008-11-03
TWI626056B (zh) 2018-06-11
JP6061747B2 (ja) 2017-01-18
TNSN08189A1 (en) 2009-10-30
US20130171167A1 (en) 2013-07-04
JP2016020377A (ja) 2016-02-04
JP2013166757A (ja) 2013-08-29
PT1940465E (pt) 2012-10-03
CY1120018T1 (el) 2018-12-12
RU2468817C2 (ru) 2012-12-10
TWI537003B (zh) 2016-06-11

Similar Documents

Publication Publication Date Title
LUC00078I2 (fr) Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta
WO2007064972A3 (fr) Anticorps monoclonaux et utilisation de ceux-ci
EP2397499A3 (fr) Anticorps humains à neutralisation anti-B7RP1
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
IL193444A (en) Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
WO2007042261A3 (fr) Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
MA29975B1 (fr) Antagonistes de la neuropiline
EA201200795A1 (ru) Связывающие элементы для пептида с5а с высоким ингибирующим действием
NO20062767L (no) Immunoglobuliner
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
WO2008033333A3 (fr) Variants de la famille il-1
NO20076663L (no) Immunoglobuliner
WO2007057748A3 (fr) Utilisation du colostrum pour la prophylaxie des syndromes grippaux
WO2008100628A3 (fr) Mimétiques de la glutathione peroxydase pour le traitement de maladies neurodégénératives, pulmonaires et inflammatoires
EP2290077A3 (fr) Anticorps naturels IgM et leur inhibiteurs
WO2006109045A3 (fr) Anticorps et leurs utilisations
HK1177471A (en) Anti-inflammatory antibodies and uses therefor
WO2004087742A3 (fr) Peptides et substances mimetiques pour la diminution de symptomes du syndrome de choc toxique et d'un choc septique
WO2006128911A3 (fr) Utilisation d'isoformes d'il-18bp dans le traitement et/ou la prevention de maladies inflammatoires neurologiques
WO2007009700A3 (fr) Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique